Biocartis Group NV is a Belgium-based company, which specializes in the development of molecular diagnostic systems, especially for the treatment of cancers and infectious diseases, the products ensure the analysis of biomolecules associated with risk factors, early detection, treatment selection and monitoring of disease. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes.

Econocom Group specializes in the management of IT and telecom infrastructures for businesses throughout Europe, U.S. and China. Co. designs and implements products and services for SMEs, corporations or public authorities. It operates through four complementary businesses: IT products and solutions, distributed infrastructures (outsourcing, maintenance and consulting), telecom services and administrative and financial management of ICT assets. Co.'s business segments are as follows: IT Financial Services; Managed Services; Products and Solutions; and Telecom Services.

IBA- Ion Beam Applications develops and markets technologies and pharmaceutical products for the healthcare sector, with a focus on cancer diagnosis and therapy. Co. is also engaged in the sterilization and ionization market. Co. operates in two primary business segments: Equipment and Pharmaceuticals. Co.'s Equipment segment encompasses development, fabrication, and services associated with medical and industrial particle accelerators, proton therapy systems, and a range of dosimetry products, while Co.'s Pharmaceuticals segment encompasses the production and distribution of radiopharmaceutical agents as well as its bioassay operations.

ThromboGenics is an integrated biopharmaceutical company based in Belgium. Co. is focused on developing and commercializing ophthalmic medicines. Co.'s primary product JETREA® (ocriplasmin), has been approved by the U.S. FDA for the treatment of symptomatic Vitreomacular Adhesion (VMA). In Europe, it has been approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. Co. is also further exploring anti-PIGF (Placental Growth Factor), formerly referred to as TB-403, for the treatment of ophthalmic and oncology indications.

Resilux is engaged in the production of PET (polyethylene teraphthalate) packaging in the form of preforms and bottles. The preforms are blown into bottles by Co. or by the customer, and then filled with water, soft drinks, edible oils, ketchup, detergents, milk, beer, fruit juices, etc. Co. produces preforms for many applications and in various weights, colors and forms. Preforms and bottles are produced for both single use and multiple use. Co. offers various solutions for barrier-sensitive products.